R&D channel feed – Endpoints News

R&D channel feed

FDA rejects bladder cancer therapy developed by Patrick Soon-Shiong’s ImmunityBio

3 years ago

Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug

3 years ago

Boehringer brings early data for GLP-1 receptor showing almost 15% weight loss after 46 weeks

3 years ago

When orphan drugs are blockbusters: Researchers call on Congress to make companies pay back tax credits

3 years ago

As Zynlonta sales disappoint, ADC Therapeutics cuts staff and preclinical programs

3 years ago

FDA lifts partial hold on Salarius' Ewing sarcoma drug trial

3 years ago

Updated: EQRx abandons its mission of drug price reform, will cut more than half of employees

3 years ago

Lundbeck out-licenses three candidates to Cambridge biotech

3 years ago

After Rubius collapse and brief stop at Flagship startup, Pablo Cagnoni finds new start at Incyte

3 years ago

When is a preclinical drug worth a mother lode of cash? This top 20 list offers a few answers

3 years ago

Nonhuman primate shortage worsens due to pandemic, importation challenges — study

3 years ago

NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study

3 years ago

FibroGen’s roxadustat fails a PhIII clinical trial

3 years ago

Bayer opens cell, gene therapy incubator in Cambridge

3 years ago

With Eylea in decline, Regeneron awaits FDA approval for higher dose of blockbuster

3 years ago

NIH contributes billions to new drug development. GAO says patents don't tell the full story

3 years ago

Ionis chops two PhII programs in acromegaly and beta thalassemia

3 years ago

Roche doubles down on organoids, human model systems with new research institute

3 years ago

Valneva, Pfizer delay their Lyme disease vaccine submission to 2026

3 years ago

Belldegrun-backed biotech real estate group nabs $130M to construct eight-story hub in Philly

3 years ago

“The grim veil has been lifted.” Excitement, and questions, mount over Lilly’s positive Alzheimer’s drug data

3 years ago

ImmunoGen’s ovarian cancer treatment helps patients live longer than chemo in confirmatory trial

3 years ago

Lilly’s Alzheimer’s drug donanemab slows cognitive decline by 35% in PhIII, setting up showdown with Eisai’s Leqembi

3 years ago

Decentralized trials: FDA lays out its thinking in new draft guidance

3 years ago

First page Previous page 85 86 878889 90 91 Next page Last page